Overall sensitivity
89.8 percent
- EndpointStandalone suspicious-case classification
- Population1,019 FFDM and DBT examinations in two retrospective blinded studies
- Tested versionMammoSightAI
FDA-cleared profile
Neurocareai, Inc. (Dba Savelife.Ai) · Mammography/DBT · FDA-cleared (510(k))
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Evidence takeaway. Evidence from the reviewed source record: Retrospective blinded standalone evidence is exact-submission regulatory evidence; vendor marketing numbers were not substituted for FDA endpoints.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "assist radiologists in prioritizing exams within the standard-of-care image worklist for compatible FFDM and DBT screening mammograms. Utilizing an advanced artificial intelligence algorithm, MammoSightAI analyzes each mammogram and assigns a tag indicating the software’s suspicion of at least one potentially suspicious finding." … "These assigned tags are seamlessly integrated into the hospital PACS or workstation, enabling worklist prioritization or triage to help radiologists focus on the most critical cases first.". Read from the exact FDA decision document on 2026-11-14.
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Overall standalone sensitivity; see study context.
Overall standalone specificity; see study context.
89.8 percent
95 percent
K252954
Reference standard used biopsy/clinical evidence and follow-up categories described in the summary.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Compatible FFDM and DBT DICOM screening examinations; validation population was women aged 35 years and older.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary
Source context, not route validation: Current SaveLife.AI family material describes DICOM integration with PACS/RIS and RadioViewAI/ConnectAI workflows.
Scope: Product family. Not an exact submission interface guarantee.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-05 · SaveLife.AI AI Suite
Source context, not route validation: The summary describes both on-premises and cloud deployment.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary
Source context, not route validation: Suspicious or blank worklist tag, a nondiagnostic Secondary Capture preview and Structured Report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary
Unresolved route: Suspicious or blank worklist tag, a nondiagnostic Secondary Capture preview and Structured Report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-05 · MammoSightAI: K252954 clearance and 510(k) summary
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Not an exact submission interface guarantee.
Vendor statements, not attestations. The reports are NDA-gated and were not read; the trust center names SaveLife.AI/Neurocareai generally and does not scope the claims to MammoSightAI or any specific release; exact-release scope is not established.
Current AI Suite materials describe PACS/RIS DICOM integration.
product family · checked 2026-09-05Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No stored literature or trial candidates; empty metadata snapshots were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Bounded web search on 2026-10-26 (query: "Savelife.AI Neurocareai reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
9 sources - 3 history items
Scope: regulatoryIdentity, purpose, modality, anatomy
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: identity, clinical, implementation, evidence
Scope: product_family_implementation
Scope: security
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Medcognetics, Inc.
Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
VinBigData Joint Stock Company
The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.
MedCognetics, Inc.
Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
DeepHealth, Inc.
Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history